Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://www.ncbi.nlm.nih.gov/pubmed/26543359
http://dx.doi.org/10.2147/COPD.S90948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://www.ncbi.nlm.nih.gov/pubmed/26543359
http://dx.doi.org/10.2147/COPD.S90948

Ejemplares similares